The Immunoglobulin Gene Usage for Anti-V3 Monoclonal Antibodies
抗 V3 单克隆抗体的免疫球蛋白基因用途
基本信息
- 批准号:8093754
- 负责人:
- 金额:$ 18.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-08-23 至 2011-08-22
- 项目状态:已结题
- 来源:
- 关键词:AddressAntibodiesAntigensBindingCharacteristicsComplementarity Determining RegionsComplexCrystallographyDataDevelopmentEpitopesExhibitsGene FamilyGenesGlycoproteinsHIVHIV Envelope Protein gp120HIV vaccineHIV-1HIV-1 vaccineHeterogeneityHumanImmunogeneticsImmunoglobulin GenesImmunoglobulinsIndividualLaboratoriesLightMeasuresMonoclonal AntibodiesNaturePeptidesPeripheral Blood LymphocyteProductionResearch DesignRoleSequence AnalysisSerumStructureTestingUrsidae FamilyV3 LoopVirusbasecross reactivitydesignimmunogenicneutralizing antibodypathogenresearch studyvaccine development
项目摘要
DESCRIPTION (provided by applicant): These studies are designed to examine 44 human anti-V3 monoclonal antibodies (mAbs) with respect to how the immunoglobulin (Ig) variable heavy (VH) and variable light (VL) chain gene usage determines Ab cross-reactivity and function. The studies are based on previous findings in that human Abs against different pathogens exhibit preferential VH gene usage. In this application we focus on Abs to the V3 loop, a hypervariable region of the HIV-1 gp120 envelope glycoprotein, which may require very different structural features in the Abs that bind to it in order to accommodate its sequence heterogeneity. Human anti-V3 mAbs have the capacity to neutralize primary isolates and this suggests that Abs against V3 might constitute an important target for HIV vaccine. The most useful approach to study the role of Ig genes in targeting particular epitopes is the analysis of the VH and VL germline gene usage among mAbs. Therefore, in Aim 1 we will evaluate the VH and VL gene usage for neutralizing anti-V3 mAbs and compare this with mAbs specific to the CD4-binding domain, the CD4i epitope, and gp41. Preliminary analysis of several human anti-V3 mAbs has revealed a preferential usage of the VH5-51 gene segment that is rarely used within the normal repertoire. Complete analysis of the 44 anti-V3 mAbs will be used to determine the extent of the biased gene usage. In Aim 2, we will address the question of whether there is a correlation between VH and/or VL gene usage and cross-neutralizing activity of anti-V3 mAbs. Pilot experiments support the hypothesis that preferentially used VH genes may encode mAbs displaying broader cross-reactivity and more efficient neutralization. In Aim 3, we will examine the relationship between gene usage and mAb activity by crystallography, analyzing the antigen-interacting residues in VH and/or VL and sequence analysis of the germline genes encoding these mAbs. We hypothesize that the germline genes preferentially used by the V3 mAbs may encode residues which interact with the antigen and remain intact in the CDRs of the antibody. The results impact on understanding the immunogenetics of Ab production which could have critical implications for HIV vaccine development.
NARRATIVE: In this proposal, we will study immunoglobulin gene usage for the human neutralizing antibodies against the V3 region of HIV-1. Our preliminary results suggest that there is a preferential use of one particular immunoglobulin gene segment for making anti-V3 antibodies and that the resultant antibodies are very efficient at neutralizing viruses from different HIV-1 subtypes. Identifying the immunoglobulin genes that encode the most potent neutralizing antibodies will be essential when designing an effective HIV vaccine with capability of inducing protective antibodies.
描述(由申请方提供):这些研究旨在检查44种人抗V3单克隆抗体(mAb)的免疫球蛋白(IG)可变重链(VH)和可变轻链(VL)基因使用如何决定Ab交叉反应性和功能。这些研究是基于先前的发现,即针对不同病原体的人Ab表现出优先的VH基因使用。在这个应用程序中,我们专注于抗体的V3环,HIV-1 gp 120包膜糖蛋白的高变区,这可能需要非常不同的结构特征的抗体结合,以适应其序列的异质性。人源抗V3单克隆抗体具有中和原代分离株的能力,这表明抗V3单克隆抗体可能成为HIV疫苗的重要靶点。研究IG基因在靶向特定表位中的作用的最有用的方法是分析mAb中VH和VL种系基因的使用。因此,在目的1中,我们将评估中和抗V3 mAb的VH和VL基因使用,并将其与特异性针对CD 4结合结构域、CD 4 i表位和gp 41的mAb进行比较。对几种人抗V3单克隆抗体的初步分析揭示了VH 5 -51基因片段的优先使用,其在正常库中很少使用。将使用44种抗V3 mAb的完整分析来确定偏倚基因使用的程度。在目的2中,我们将解决VH和/或VL基因使用与抗V3 mAb的交叉中和活性之间是否存在相关性的问题。初步实验支持这样的假设,即优先使用的VH基因可以编码显示更广泛的交叉反应性和更有效的中和的mAb。在目标3中,我们将通过结晶学检查基因使用与mAb活性之间的关系,分析VH和/或VL中的抗原相互作用残基以及编码这些mAb的种系基因的序列分析。我们假设V3 mAb优先使用的生殖系基因可能编码与抗原相互作用并在抗体CDR中保持完整的残基。这些结果影响了对抗体产生的免疫遗传学的理解,这可能对HIV疫苗的开发具有重要意义。
叙述:在这项计划中,我们将研究免疫球蛋白基因的用途,为人类中和抗体对HIV-1的V3区。我们的初步结果表明,有一个特定的免疫球蛋白基因片段的优先使用,用于制造抗V3抗体,并得到的抗体是非常有效的中和来自不同的HIV-1亚型的病毒。在设计具有诱导保护性抗体能力的有效HIV疫苗时,鉴定编码最有效中和抗体的免疫球蛋白基因将是必不可少的。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MIROSLAW K GORNY其他文献
MIROSLAW K GORNY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MIROSLAW K GORNY', 18)}}的其他基金
Protective role of V2 antibodies induced at mucosal tissues in macaques
猕猴粘膜组织中诱导的 V2 抗体的保护作用
- 批准号:
9187975 - 财政年份:2015
- 资助金额:
$ 18.2万 - 项目类别:
Production of Cross-Neutralizing HIV-1 Antibodies from Single B Cells
从单个 B 细胞生产交叉中和 HIV-1 抗体
- 批准号:
8786133 - 财政年份:2014
- 资助金额:
$ 18.2万 - 项目类别:
Training Program on HIV Diversity and Drug Resistance-Enhancing Research Capacity
艾滋病毒多样性和增强耐药性研究能力培训计划
- 批准号:
9225255 - 财政年份:2013
- 资助金额:
$ 18.2万 - 项目类别:
Induction of HIV Neutralizing Antibodies by Targeting Macaque B Cell Receptors
通过靶向猕猴 B 细胞受体诱导 HIV 中和抗体
- 批准号:
8743681 - 财政年份:2013
- 资助金额:
$ 18.2万 - 项目类别:
Induction of HIV Neutralizing Antibodies by Targeting Macaque B Cell Receptors
通过靶向猕猴 B 细胞受体诱导 HIV 中和抗体
- 批准号:
8329172 - 财政年份:2012
- 资助金额:
$ 18.2万 - 项目类别:
Induction of HIV Neutralizing Antibodies by Targeting Macaque B Cell Receptors
通过靶向猕猴 B 细胞受体诱导 HIV 中和抗体
- 批准号:
8462899 - 财政年份:2012
- 资助金额:
$ 18.2万 - 项目类别:
Production of Cross-Neutralizing HIV-1 Antibodies from Single B Cells
从单个 B 细胞生产交叉中和 HIV-1 抗体
- 批准号:
8262818 - 财政年份:2011
- 资助金额:
$ 18.2万 - 项目类别:
Improving Research Capacity in Cameroon for Studies on HIV-Associated Malignancie
提高喀麦隆艾滋病毒相关恶性肿瘤的研究能力
- 批准号:
8309398 - 财政年份:2010
- 资助金额:
$ 18.2万 - 项目类别:
相似海外基金
Rationally guided discovery platform for monoclonal antibodies against carbohydrate antigens using virus-like particle conjugate immunization and high throughput selection
使用病毒样颗粒缀合物免疫和高通量选择的合理引导的针对碳水化合物抗原的单克隆抗体的发现平台
- 批准号:
10574738 - 财政年份:2023
- 资助金额:
$ 18.2万 - 项目类别:
Assessing the role of liver stage antigens-specific antibodies against Plasmodium falciparum liver stage infection
评估肝期抗原特异性抗体对抗恶性疟原虫肝期感染的作用
- 批准号:
10392870 - 财政年份:2021
- 资助金额:
$ 18.2万 - 项目类别:
Generation of antibodies specific for optimal non-HRP2 malaria diagnostic antigens
生成最佳非 HRP2 疟疾诊断抗原的特异性抗体
- 批准号:
10092930 - 财政年份:2020
- 资助金额:
$ 18.2万 - 项目类别:
Generation of antibodies specific for optimal non-HRP2 malaria diagnostic antigens
生成最佳非 HRP2 疟疾诊断抗原的特异性抗体
- 批准号:
9896170 - 财政年份:2020
- 资助金额:
$ 18.2万 - 项目类别:
Interrogation of cell surface antigens on B lineage cells using structurally unique variable lymphocyte receptor antibodies of the evolutionarily distant sea lamprey
使用进化遥远的海七鳃鳗结构独特的可变淋巴细胞受体抗体询问 B 谱系细胞上的细胞表面抗原
- 批准号:
433456 - 财政年份:2020
- 资助金额:
$ 18.2万 - 项目类别:
Operating Grants
Investigations of interactions between various natural antibodies and food-derived antigens
研究各种天然抗体与食物源性抗原之间的相互作用
- 批准号:
19K15765 - 财政年份:2019
- 资助金额:
$ 18.2万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Identifying Kawasaki Disease-Specific Antibodies and Antigens
识别川崎病特异性抗体和抗原
- 批准号:
9932769 - 财政年份:2018
- 资助金额:
$ 18.2万 - 项目类别:
Novel Scoring Methods for Interactions between Antibodies and Antigens
抗体和抗原之间相互作用的新评分方法
- 批准号:
BB/P504713/1 - 财政年份:2017
- 资助金额:
$ 18.2万 - 项目类别:
Training Grant
Novel Scoring Methods for Interactions between Antibodies and Antigens
抗体和抗原之间相互作用的新评分方法
- 批准号:
1932904 - 财政年份:2017
- 资助金额:
$ 18.2万 - 项目类别:
Studentship
SBIR Phase II: Automated Design Methods of Antibodies Directed to Protein and Carbohydrate Antigens
SBIR II 期:针对蛋白质和碳水化合物抗原的抗体的自动化设计方法
- 批准号:
1632399 - 财政年份:2016
- 资助金额:
$ 18.2万 - 项目类别:
Standard Grant














{{item.name}}会员




